• Je něco špatně v tomto záznamu ?

Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies

L. Vernerová, V. Horváthová, T. Kropáčková, M. Vokurková, M. Klein, M. Tomčík, S. Oreská, M. Špiritović, H. Štorkánová, B. Heřmánková, K. Kubínová, O. Kryštůfková, H. Mann, J. Ukropec, B. Ukropcová, J. Vencovský

. 2020 ; 59 (9) : 2491-2501. [pub] 20200901

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012229

Grantová podpora
NV16-33746A MZ0 CEP - Centrální evidence projektů

OBJECTIVES: The aim of this study was to investigate the systemic and skeletal muscle levels of atrophy-associated myokines in patients with idiopathic inflammatory myopathies (IIM) and their association with clinical characteristics of myositis. METHODS: A total of 94 IIM patients and 162 healthy controls were recruited. Of those, 20 IIM patients and 28 healthy controls underwent a muscle biopsy. Circulating concentrations of myostatin, follistatin, activin A and TGF-β1 were assessed by ELISA. The expression of myokines and associated genes involved in the myostatin signalling pathway in muscle tissue was determined by real-time PCR. RESULTS: We report decreased levels of circulating myostatin (median 1817 vs 2659 pg/ml; P = 0.003) and increased follistatin (1319 vs 1055 pg/ml; P = 0.028) in IIM compared with healthy controls. Activin A levels were also higher in IIM (414 vs 309 pg/ml; P = 0.0005) compared with controls. Myostatin was negatively correlated to muscle disease activity assessed by physician on visual analogue scale (MDA) (r = -0.289, P = 0.015) and positively to manual muscle testing of eight muscles (r = 0.366, P = 0.002). On the other hand, follistatin correlated positively with MDA (r = 0.235, P = 0.047). Gene expression analysis showed higher follistatin (P = 0.003) and myostatin inhibitor follistatin-like 3 protein (FSTL3) (P = 0.008) and lower expression of activin receptor type 1B (ALK4) (P = 0.034), signal transducer SMAD3 (P = 0.023) and atrophy marker atrogin-1 (P = 0.0009) in IIM muscle tissue compared with controls. CONCLUSION: This study shows lower myostatin and higher follistatin levels in circulation and attenuated expression of myostatin pathway signalling components in skeletal muscle of patients with myositis, a newly emerging pattern of the activin A-myostatin-follistatin system in muscle wasting diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012229
003      
CZ-PrNML
005      
20210507104309.0
007      
ta
008      
210420s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/kez651 $2 doi
035    __
$a (PubMed)31990347
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vernerová, Lucia $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague
245    10
$a Alterations in activin A-myostatin-follistatin system associate with disease activity in inflammatory myopathies / $c L. Vernerová, V. Horváthová, T. Kropáčková, M. Vokurková, M. Klein, M. Tomčík, S. Oreská, M. Špiritović, H. Štorkánová, B. Heřmánková, K. Kubínová, O. Kryštůfková, H. Mann, J. Ukropec, B. Ukropcová, J. Vencovský
520    9_
$a OBJECTIVES: The aim of this study was to investigate the systemic and skeletal muscle levels of atrophy-associated myokines in patients with idiopathic inflammatory myopathies (IIM) and their association with clinical characteristics of myositis. METHODS: A total of 94 IIM patients and 162 healthy controls were recruited. Of those, 20 IIM patients and 28 healthy controls underwent a muscle biopsy. Circulating concentrations of myostatin, follistatin, activin A and TGF-β1 were assessed by ELISA. The expression of myokines and associated genes involved in the myostatin signalling pathway in muscle tissue was determined by real-time PCR. RESULTS: We report decreased levels of circulating myostatin (median 1817 vs 2659 pg/ml; P = 0.003) and increased follistatin (1319 vs 1055 pg/ml; P = 0.028) in IIM compared with healthy controls. Activin A levels were also higher in IIM (414 vs 309 pg/ml; P = 0.0005) compared with controls. Myostatin was negatively correlated to muscle disease activity assessed by physician on visual analogue scale (MDA) (r = -0.289, P = 0.015) and positively to manual muscle testing of eight muscles (r = 0.366, P = 0.002). On the other hand, follistatin correlated positively with MDA (r = 0.235, P = 0.047). Gene expression analysis showed higher follistatin (P = 0.003) and myostatin inhibitor follistatin-like 3 protein (FSTL3) (P = 0.008) and lower expression of activin receptor type 1B (ALK4) (P = 0.034), signal transducer SMAD3 (P = 0.023) and atrophy marker atrogin-1 (P = 0.0009) in IIM muscle tissue compared with controls. CONCLUSION: This study shows lower myostatin and higher follistatin levels in circulation and attenuated expression of myostatin pathway signalling components in skeletal muscle of patients with myositis, a newly emerging pattern of the activin A-myostatin-follistatin system in muscle wasting diseases.
650    _2
$a aktivinové receptory typu I $x genetika $7 D030201
650    _2
$a korelace dat $7 D000078331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a folistatin $x analýza $7 D038681
650    _2
$a proteiny související s folistatinem $x genetika $7 D038702
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a svalové proteiny $x genetika $7 D009124
650    12
$a kosterní svaly $x metabolismus $x patologie $7 D018482
650    12
$a svalová atrofie $x metabolismus $x patologie $7 D009133
650    12
$a myozitida $x krev $x diagnóza $x etiologie $x patofyziologie $7 D009220
650    _2
$a myostatin $x analýza $7 D055435
650    _2
$a posouzení stavu pacienta $7 D062072
650    _2
$a fyzikální vyšetření $x metody $7 D010808
650    _2
$a proteinligasy komplexu SCF $x genetika $7 D044843
650    _2
$a signální transdukce $7 D015398
650    _2
$a protein Smad3 $x genetika $7 D051900
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horváthová, Veronika $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Kropáčková, Tereza $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Vokurková, Martina $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague
700    1_
$a Klein, Martin $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Tomčík, Michal $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Oreská, Sabína $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Špiritović, Maja $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
700    1_
$a Štorkánová, Hana $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Heřmánková, Barbora $u Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic
700    1_
$a Kubínová, Kateřina $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Kryštůfková, Olga $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Mann, Heřman $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
700    1_
$a Ukropec, Jozef $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava
700    1_
$a Ukropcová, Barbara $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Vencovský, Jiří $u Division of Experimental Rheumatology, Institute of Rheumatology, Prague $u Department of Rheumatology, First Faculty of Medicine
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 59, č. 9 (2020), s. 2491-2501
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31990347 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507104307 $b ABA008
999    __
$a ok $b bmc $g 1650573 $s 1132608
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 59 $c 9 $d 2491-2501 $e 20200901 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
GRA    __
$a NV16-33746A $p MZ0
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace